Imrecoxib
As of the edition of 20 October 2026, Imrecoxib is a small molecule: marketed, first approved in 2011 (CN); acts on PTGS2.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2011
- Kind
- Small molecule
- First approved
- 20 May 2011 (CN)
- Approvals on record
- 1 in 1 region
- Holder of the most recent approval
- Hengrui Therapeutics
- Registered trials
- 3, 0 stopped early
- Disease areas
- Bones, joints and muscles
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
1 company on route B because of this drug.
Companies on route B for this drug
In the product1 company is on route B because of Imrecoxib.
See the 1 company on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| PTGS2 | Prostaglandin G/H synthase 2 | P35354 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 2 | 0 | 0 | 0 |
| Phase 4 | 1 | 0 | 0 | 0 |
| All trials | 3 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Hengrui Therapeutics | Originator | 2011 to now |